¹**Title:** *HLA-A*02:01* allele is associated with decreased risk and a longer survival in

²pancreatic cancer: Results from an exhaustive analysis of the *HLA* variation in PDAC

3 **Authors:** Alberto Langtry¹, Raul Rabadan², Lola Alonso¹, Casper van Eijck^{1,3}, 5 Teresa Macarulla⁴, Rita T Lawlor⁵, Alfredo Carrato⁶, Rafael Alvarez-Gallego⁷, Mar 6 Iglesias⁸, Xavier Molero⁹, J Matthias Löhr¹⁰, Christopher W Michalski¹¹, José Perea¹², 7 Michael O'Rorke¹³, Víctor M Barberà¹⁴, Adonina Tardón¹⁵, Antoni Farré¹⁶, Luís 8 Muñoz-Bellvís¹⁷, Tatjana Crnogorac-Jurcevic¹⁸, Enrique Domínguez-Muñoz¹⁹, 9 Thomas Gress²⁰, William Greenhalf²¹, Linda Sharp²², Sergio Sabroso-Lasa¹, Ioan 10 Filip², Gaby Strijk³, Florian Castet⁴, Joaquim Balsells⁹, Eithne Costello²¹, Jörg 11 Kleeff²³, Bo Kong²⁴, Josefina Mora¹⁶, Damian O'Driscoll²⁵, Aldo Scarpa⁵, Weimin 12 Ye^{26} , Francisco X. Real²⁷, Núria Malats^{1*}, Evangelina López de Maturana^{1*}, on behalf 13 of the PanGenEU Investigators²⁸

 14 14

¹⁵**Authors' affiliations:**

- ¹⁶(1) Genetic and Molecular Epidemiology Group, Spanish National Cancer 17 Research Center (CNIO), and CIBERONC, Madrid, Spain.
- ¹⁸(2) Department of Systems Biology, Columbia University, New York, NY, USA.
- ¹⁹(3) Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
- ²⁰(4) Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall 21 d'Hebron, Barcelona, Barcelona, Spain.
- ²²(5) ARC-Net Center for Applied Research on Cancer, Department of Diagnostics 23 and Public Health and Department of Engineering for Innovation Medicine, 24 University of Verona, Verona, Italy.
- ²⁵(6) Department of Oncology, Ramón y Cajal University Hospital, IRYCIS, Alcala 26 University, Madrid, and CIBERONC, Spain.
- ²⁷(7) HM CIOCC Madrid (Centro Integral Oncológico Clara Campal). Hospital ²⁸Universitario HM Sanchinarro. Instituto de Investigación Sanitaria HM ²⁹Hospitales. Facultad HM de Ciencias de la Salud de la Universidad Camilo 30 José Cela.
- ³¹(8) Hospital del Mar—Parc de Salut Mar, Barcelona, and CIBERONC, Spain.
- ³²(9) Hospitals Universitaris Arnau de Vilanova i Santa Maria, IRBLleida, UdL, 33 25198, Lleida; and CIBEREHD, Madrid, Spain.

87 datasets (UK Biobank, TCGA, PAN-NGS trial, and Caris trial). *HLA-A*02:01and* ⁸⁸*HLA-B*49* alleles were linked to a decreased risk of PDAC, whereas *HLA-B*39*, ⁸⁹*HLA-DPB1*04,* and *HLA-A*26:01* were directly associated with increased risk. 90 PDAC patients carrying the *HLA-A*02:01* allele also showed lower mortality rates, 91 with the effect being more pronounced in those with $KRAS^{G12V}$ mutations, pointing to 92 a host*tumor genetic interaction. This research highlights *HLA-A*02:01*, found in ⁹³20% of Europeans, as a marker for reduced PDAC risk and mortality, especially in 94 *KRAS*^{G12V} mutated tumors. Results from this study could enhance personalized ⁹⁵medicine for PDAC by identifying patients who may benefit from regular screenings

- 96 through tailored risk assessments. Importantly, our findings are crucial for stratifying
- 97 PDAC patients based on their genetic background and tumor mutational profile, which
- 98 can guide treatment strategies.
- 99

¹⁰⁰**INTRODUCTION**

101 Pancreatic cancer has a dismal prognosis with a 5-year survival rate of $5-10\%$ (1–3) 102 and a 10-year survival rate of 1% (4). Worryingly, it is expected to become the second 103 cause of cancer-related deaths in the USA by 2030 if action is not taken (5). Pancreatic 104 ductal adenocarcinoma (PDAC) is the most common form of these neoplasms. So far, 105 great efforts are being made to advance its diagnosis and detect tumors at early stages 106 to improve survival $(6-8)$. Identifying the genetic and non-genetic factors involved in ¹⁰⁷PDAC etiology is crucial for defining high-risk individuals who would benefit from 108 detecting the tumor when it is still curable. However, there is no definition of high-109 risk individuals for sporadic PDAC, those representing 90% of the burden of the 110 disease.

¹¹¹We previously reported an inverse association between PDAC risk and nasal 112 allergies, asthma, and autoimmune diseases $(9,10)$, conditions characterized by an 113 overactive immune response. Furthermore, our recent multilayered GWAS approach ¹¹⁴(11) identified a hotspot in the Major Histocompatibility Complex (*MHC*) region, ¹¹⁵where the alternative allele of the top targeted Human Leukocyte Antigen *(HLA) G* 116 gene was associated with increased PDAC risk (p-value= $1.8x10^{-4}$). In addition, several ¹¹⁷GWAS hits at this region have been associated with the risk of other cancer types like 118 breast (12) or lung cancer $(13,14)$, as well as with well-established PDAC risk and 119 protective factors such as chronic immune-related diseases $(15,16)$, diabetes $(17,18)$, 120 smoking (19), asthma (20,21), and nasal allergies (22). The lack of GWAS-reported ¹²¹PDAC genetic susceptibility loci in the *MHC* region might be because SNPs are not 122 fully capturing the variability of the *MHC*. On the other hand, at the tumor level, Filip ¹²³et al. (2023) (23) reported that Allele-Specific Expression loss of the *HLA* class I 124 genes in PDAC, among other cancers, is associated with a worse prognosis.

125 The *MHC* is essential for the proper response of the immune system against 126 tumor cells (24). The *MHC* genetic complex is a dense cluster of genes located at the ¹²⁷6p21.1-21.3 chromosome cytoband (28,477,797-33,448,354 bp, GRCh37), and it 128 includes three *HLA* sub-regions. *HLA* class I can be classified into classical (*HLA*-A, -129 B, and -C) and non-classical genes (*HLA*-*E*, -*F*, and -*G*). *HLA* class II genes are *HLA*-¹³⁰*DR*, -*DQ*, and -*DP*. HLA class I and II proteins present intracellular and extracellular 131 peptides to $CD8^+$ and $CD4^+$ T-cells, respectively (25,26). The *MHC* region also shows 132 an extensive linkage disequilibrium (27) . As a consequence of its complexity, the role 133 of this region has not yet been studied in-depth in relation to the risk of cancer and, 134 more specifically, PDAC.

135 Here, we report an exhaustive study on PDAC genetic susceptibility associated 136 with the *MHC* region variation on *HLA* class I and II alleles, haplotypes, and amino 137 acids (**Fig. 1**). We performed association analyses at the *HLA* allele and haplotype ¹³⁸levels in PanGenEU, one of the largest PDAC case-control studies with extensive 139 standardized clinical and epidemiological data annotation. We then tested these 140 associations in an independent population, the UK Biobank (UKB), and computed 141 global risk estimates by meta-analyzing the results from the two consortia. We also 142 deliver for the first time an estimate of the heritability for PDAC risk explained by the ¹⁴³*HLA* class I and II variation. Furthermore, we used the resources from TCGA, UKB, 144 and PanGenEU to conduct a meta-analysis on the HLA alleles' overall survival (OS) 145 associations. Finally, we assessed the association between the most promising alleles 146 and common *KRAS* mutations using TCGA data and validated results with PAN-NGS 147 and Caris trials. Altogether, our findings underscore the role of the *HLA* region in ¹⁴⁸PDAC genetic susceptibility and prognosis. Our findings may have implications for 149 the design of mutant KRAS-based vaccines in PDAC.

¹⁵⁰**RESULTS**

¹⁵¹*Characteristics of the study populations*

152 The characteristics of the PanGenEU, UK Biobank, and TCGA study populations are ¹⁵³available in **Supplementary Table S1**. PanGenEU participants were Caucasian from 154 Spain (58.8%), Italy (22.6%), Sweden (7.9%), Germany (6.7%), UK (3.7%), and 155 Ireland (0.2%) . The average age was similar between cases and controls in each study 156 population; however, UKB controls were, on average, younger than cases. A slightly ¹⁵⁷lower proportion of females across the studies was observed for both cases and 158 controls. In the PanGenEU and UKB populations, cases were more frequently 159 smokers and diabetic, while controls had a higher prevalence of asthma and allergies. 160 Finally, the median survival was shorter for UKB patients than for TCGA and 161 PanGenEU patients. As expected based on study design, TCGA included a higher 162 proportion of patients with early-stage tumors than PanGenEU cases. We also 163 observed significant differences in the stage of the tumors across populations, being 164 the Caris clinical trial the population with the highest proportion of stage III-IV PDAC 165 tumors. The median survival time of the UKB patients was significantly shorter 166 compared to the PanGenEU, TCGA, Erasmus, and Caris patients. Finally, neoadjuvant 167 and adjuvant settings were significantly different between the Erasmus and Caris 168 populations.

169
1

¹⁷⁰*Association analyses between HLA alleles and PDAC risk*

171 HLA class I and class II alleles explain 11% of the PDAC risk. Bayesian multi kernel-172 based regression allowed us to obtain the genetic and residual variance components 173 $(\sigma_{HLA-I}^2 = 0.013, \sigma_{HLA-II}^2 = 0.010, \text{ and } \sigma_e^2 = 0.174)$ and therefore, the heritability 174 estimates for *HLA* class I and class II alleles were: $h_{HLA-I}^2 = 0.06$ and $h_{HLA-II}^2 = 0.05$.

Supplementary Fig. S1A and **S1B** show the landscape of *HLA* class I and II alleles at two-field level in PanGenEU and UKB populations, respectively. *HLA-B* was the most polymorphic *MHC* gene in both populations: 97/298 (32.6%), two-field *HLA* alleles in the PanGenEU and 108/306 (35.3%) in UKB. Some alleles, like *HLA-DPA1*01:03*, showed large variability across populations. In general, the AF matched 180 expected European frequencies (28). The AF in PanGenEU showed good correlations with the T1DGC reference panel (R=0.92 and R=0.86, for one- (allele group) and two-fields (HLA protein) *HLA* alleles, see, **Supplementary Fig. S2A and S2B**) and moderate correlation with UKB (R=0.57, see **Supplementary Fig. S3**). **Supplementary Table S2** summarizes the number of *HLA* class I and II alleles 185 considered in the association analyses after filtering out those with poor imputation 186 quality and low AF.

187 In our comprehensive meta-analysis of the PanGenEU and UKB populations, 188 the following four alleles yielded significant associations with PDAC risk: *HLA-*189 *A**02:01 (OR=0.86, p-value=1.88x10⁻³), *HLA-B**49 (OR=0.68, p-value=3.81x10⁻²), 190 *HLA-B**39 (OR=1.42, p-value=1.99x10⁻²), and *HLA-DPB1**04 (OR=1.1, p-191 value=2.86x10⁻²) (**Fig. 2**). After multiple testing correction, only the $HLA-A*02:01$ 192 remained significant (OR=0.86, corrected p-value= 2.25×10^{-2} , **Supplementary Table** ¹⁹³**S3**). We also explored the association between the above-mentioned *HLA* alleles and 194 the established PDAC risk factors. Interestingly, we observed a significant inverse 195 association between *HLA-B**39 and nasal allergies, which is protective against PDAC 196 (OR=0.84, p-value= $1.15x10^{-4}$, see **Fig. 2C**).

197 Furthermore, the PanGenEU study identified one allele significantly associated 198 with PDAC: the *HLA* class I $A*26:01$ (OR=1.75, corrected p-value=4.17x10⁻²). 199 Individuals carrying this allele, present in 5% of the PanGenEU study population,

²⁰⁰showed a higher risk of developing PDAC (OR=1.74, **Supplementary Table S4**). ²⁰¹Additionally, when both controls and cases were combined to increase statistical 202 power, we found that this allele was significantly and inversely associated with nasal 203 allergies (OR=0.56, p-value=2.87 $x10^{-2}$) and, although non-significantly, with asthma 204 (OR=0.68, p-value= $2.2x10^{-1}$, **Supplementary Fig. S4A**). However, we did not 205 replicate the association between $HLA-A*26:01$ and PDAC risk in the UKB study ²⁰⁶(**Supplementary Table S5**) nor the meta-analysis, although the direction of the 207 association was the same (OR=1.07, p-value= 9.88×10^{-1}).

208

²⁰⁹*Cumulative PDAC risk score for the most promising alleles*

²¹⁰We estimated cumulative PDAC risk by combining known risk and protective factors 211 and adding PDAC-associated *HLA* alleles. In a meta-analysis with the UK Biobank, 212 individuals with the abovementioned non-genetic high-risk conditions had 2.8 times 213 higher PDAC risk. By including either *HLA-B**39 or *HLA-DPB1**04 alleles, the ORs 214 increased to 5.28 and 3.34, respectively (**Table 1**), though not statistically significant 215 (p-value=1.17x10⁻¹, p-value=1.33x10⁻¹, respectively). Conversely, asthmatic or 216 allergic individuals who did not smoke, had no diabetes, nor had a family history of ²¹⁷PDAC, experienced a 62% reduction in the odds (OR=0.38) of developing PDAC. 218 Subjects who had one/two alleles of *HLA-A**02:01 further decreased their ORs to 0.32 219 and 0.27, respectively (p-value= $1.18x10^{-2}$). By including one/two copies of the *HLA*-220 *B*49* allele in the model, the OR significantly decreased to 0.19 and 0.1 (p-221 value= $2.4x10^{-2}$, **Table 1**). Additionally, in the PanGenEU study, diabetics, smokers, 222 and individuals with a family history of cancer but without asthma or allergies had 223 4.33 times higher risk of PDAC than the population in the lowest risk category. When 224 those individuals at high-risk harbor one or two copies of the *HLA-A**26:01 allele, the

225 ORs increased to 7.73 and 13.81, respectively (p-value= 2.28×10^{-2} , see **Supplementary Fig. S4B**).

Association analyses between HLA haplotypes and PDAC risk

Given the critical role of *HLA* haplotypes in immune responses, we assessed their 230 association with PDAC risk. We identified 18 haplotypes significantly associated with PDAC risk, nine of which remained significant after multiple testing correction (**Supplementary Table S6**). Two of the top five protective haplotypes carried the *HLA-A*02* allele, present in 20% of the European population and associated with 234 decreased PDAC risk in our analyses. Haplotypes harboring the *HLA-A*02* allele were 235 all protective for PDAC, some reaching an $OR~0.4$). Among the haplotypes with the lowest effect size *HLA-B*35* and *HLA-A*02* alleles were common: *HLA-B*35*/*HLA-A*0*2 (OR=0.41, 95%CI=0.18-0.94), *HLA-DRB1*13*/*HLA-B*35* (OR=0.43, 95%CI=0.38-0.5), and *HLA-DRB1*01*/*HLA-A*02* (OR=0.49, 95%CI=0.27-0.89). On the contrary, the highest risk haplotypes harbored the *HLA-DRB1*04* allele: *HLA-DRB1*04*/*HLA-B*44*/*HLA-C*07* (OR=1.19, 95%CI=1.12-1.26) and *HLA-DRB*04*/*HLA-B*14* (OR=1.28, 95%CI=1.19-1.38) (**Supplementary Table S6**).

The *HLA-A*26*, *HLA-B*39*, and *HLA-B*49* alleles were not part of the haplotypes significantly associated with PDAC risk in the meta-analysis, probably because of their low AF: *HLA-A*26*=0.02, *HLA-B*39*=0.02, and *HLA-B*49*=0.01.

HLA alleles are associated with overall survival of PDAC patients

We further assessed the role of *HLA* alleles in PDAC prognosis through a meta-248 analysis of the results from the survival analyses in PanGenEU, UK Biobank, and 249 TCGA studies. 156 *HLA* class I and II alleles overlapped between the three studies

²⁵⁰(**Supplementary Fig. S5**). The results obtained under a dominant MoI revealed that 251 patients who carried the *HLA-A*02:01* allele presented better survival than non-252 carriers (HR=0.87, p-value=3.3x10⁻², Fig. 3), indicating that a single copy of this 253 allele is enough to improve survival. On the other hand, homozygous individuals for ²⁵⁴*HLA-DPB1*04* displayed a borderline significantly worse survival under a 255 codominance model $(HR=1.19, p-value=6.3x10^{-2}$, **Supplementary Fig. S6**). 256 Additionally, carriers of $HLA-A*30:01$ (HR=1.75, p-value=1.2x10⁻²), and $HLA-A+30:01$ 257 *DPB1*09:01* (HR=3.36, p-value=1.5x10⁻³) were also associated with worse overall 258 survival compared to non-carriers (**Supplementary Fig. S7**).

260 *HLA-A*02:01 interacts with KRAS^{G12V} mutations for PDAC survival*

²⁶¹More than 90% of PDAC harbor *KRAS* mutations. We found that the PDAC 262 protective allele $HLA-A*02:01$ was associated with tumors harboring $KRAS^{\text{G12V}}$ vs. 263 other mutations in PDAC, NSCLC, and colorectal cancers (OR=1.55, p-264 value=4.65x10⁻²), and with $KRAS^{\text{G12D}}$ mutations in gastric tumors (OR=7.27, p-265 value= $6.42x10^{-3}$ (**Supplementary Table S7**).

266 Stratified analysis revealed that $HLA-A*02:01$ carriers with $KRAS^{G12V}$ tumors 267 had significantly better survival (HR=0.19, p-value= $1.3x10^{-2}$, **Fig. 4A**) than *HLA*-²⁶⁸*A**02:01 carriers with other *KRAS* mutations; importantly, survival did not differ for 269 patients with *KRAS*^{G12V} mutated tumors who did not carry the *HLA-A*02:01* allele 270 (HR=0.87, p-value=8.1x10⁻¹, Fig. 4B). Conversely, carriers of $HLA-A*02:01$ and 271 *KRAS*^{G12D} had significantly worse survival (HR=5.51, p-value=1.5x10⁻³, **Fig. 4C**) than 272 non-carriers (HR=1.13, p-value= 6.2×10^{-1} , Fig. 4D). Further stratified analyses focusing on individuals carrying either the *KRAS*^{G12V} or *KRAS*^{G12D} mutations, along ²⁷⁴with the presence or absence of the *HLA-A*02:01* allele, showed that the longer 275 survival of *KRAS*^{G12V} carriers appear to be driven by the interaction with the *HLA*-276 $A*02:01$ allele (HR=0.13, p-value=4.4x10⁻², Fig. 5A). However, for those with 277 *KRAS*^{G12D} mutated tumors, the decreased survival was mainly due to the mutation 278 itself, regardless of the HLA allele $(HR=1.21, p-value=2.2x10^{-1}$, **Fig. 5B**). 279 Interestingly, we discovered that *KRAS*^{G12D} mutated tumors, displayed a significant 280 higher expression level of IFN- γ in comparison to tumors carrying any of the other ²⁸¹*KRAS* mutations (**Supplementary Fig. S8**).

282 The interaction model in the TCGA study showed that carriers of the *HLA-*283 A^{*}02:01 allele who had a $KRAS^{\text{G12V}}$ mutated tumor had a significantly lower risk of 284 death (HR=0.14, p-value= $2.4x10^{-2}$) compared to patients with any of the other *KRAS* 285 mutations, adjusted for gender, age at diagnosis, stage, and Moffit tumor subtype. We 286 then performed a meta-analysis of the interaction between the $A*02:01$ allele and 287 *KRAS*^{G12V} mutations, including the PAN-NGS and Caris populations (**Supplementary** 288 **Fig. S9**). This interaction held significant in early-stage tumors (HR=0.25, p-289 value=1.7x10⁻², **Fig. 6A**) but not in advanced-stage (HR=0.93, p-value=8.7x10⁻¹, **Fig.** ²⁹⁰**6B**).

291

²⁹²**DISCUSSION**

²⁹³The present study represents the most exhaustive analysis of the role of the ²⁹⁴*MHC* region at the *HLA* allele and haplotype levels associated with PDAC risk and 295 prognosis. We show that different *MHC* genetic profiles recognize distinct PDAC risk 296 populations. We identified five novel susceptibility alleles in the *HLA* class I and II 297 regions associated with PDAC risk: *HLA-A**26:01, *HLA-A**02:01, *HLA-B**49, *HLA-*²⁹⁸*B**39, and *HLA-DPB1**04. Among these, *HLA-A*02:01* remained significant after 299 correcting for multiple testing, showing a notably reduced risk of PDAC

300 (metaOR=0.86, corrected p-value=2.25 $x10^{-2}$. This allele is prevalent in 20% of the ³⁰¹European population, and was present in all the protective haplotypes. Interestingly, ³⁰²HLA-A*02:01 has been found to be associated also with a decreased risk of ³⁰³melanoma (29). Importantly, we found that germline *HLA-A*02:01* carriers with ³⁰⁴PDAC from the PanGenEU, UKB, TCGA, and Caris had a survival benefit 305 (metaHR=0.87, p-value= $3.3x10^{-2}$; Fig. 3B). These findings go along with the 306 observations that *HLA-A*02:01* carriers have better survival in NSCLC (30), and 307 might have improved outcomes to immunotherapy (31), pointing to *HLA-A*02:01* as a ³⁰⁸good prognostic marker for PDAC. Notably, the *HLA-A*02:01* allele is among the 309 eligibility criteria in different cancer immunotherapy clinical trials for esophageal 310 carcinoma (32) , acute myeloid leukemia (33) , NSCLC (34) , and glioblastoma 311 (currently in phase III) (35).

³¹²Since *HLA-A*02:01* has shown a high predicted binding affinity for the *KRAS* 313 codon 12 mutation in silico-in vitro studies (36), we also assessed the association of ³¹⁴*HLA-A*02:01* with the most common hotspot *KRAS* mutations (at codons 12, 13, and ³¹⁵61) in *KRAS*-mutated cancers (PDAC, NSCLC, stomach, and colorectal) using TCGA 316 data. After adjusting for cancer type, we discovered that *HLA-A*02:01* is 317 preferentially associated with tumors harboring $KRAS^{G12V}$ mutations (OR=1.55, p-318 value=4.65x10⁻²). Remarkably, we observed that patients with $KRAS^{\text{G12V}}$ mutated 319 tumors who carried the $HLA-A*02:01$, comprising approximately 5% of the PDAC 320 patients, experienced significantly better survival compared to those without the allele. 321 This novel interaction was confirmed in an independent series of resectable (or early-322 stage) PDAC cases (PAN-NGS). Supporting this host-tumor interaction, the NEPdb 323 (https://nep.whu.edu.cn/) database, which includes data on over 17K validated human 324 immunogenic neoantigens, shows that only $KRAS^{\text{G12V}}$ and $KRAS^{\text{G12D}}$ mutations have

325 been validated to bind the $HLA-A*02:01$ protein and elicit an immune response. 326 Conversely, regardless of the HLA allele, patients with *KRAS*^{G12D}-mutant tumors had 327 significantly worse survival than those without this mutation. However, the PAN-NGS 328 and Caris independent datasets could not validate this finding.

329 Therefore, this study is a pioneer in showing that the presence of *HLA-A*02:01* 330 allele not only is associated with protection against PDAC risk but it is also associated 331 with better PDAC survival, mainly in patients with early-stage *KRAS*^{G12V} mutant tumours. Our findings could lead to an $HLA-A*02:01-KRAS^{G12V}$ classification system 333 for nearly 2% of PDAC patients with better survival. Also, we anticipate that these 334 patients may benefit from immunotherapy based on the results observed in xenograft 335 models, with the *HLA-A*02:01* showing a better response to immunotherapy due to its 336 ability to bind *KRAS*^{G12V} neoantigens (31). In contrast, approximately 40% of PDAC 337 patients with $KRAS^{\text{G12D}}$ mutated tumors demonstrated the poorest survival outcomes 338 in TCGA, independent of their *HLA* allele. This significantly narrows the therapeutic 339 options for these patients, potentially restricting them to systemic chemotherapy alone. 340 Given that *KRAS* mutations are neoantigens capable of binding the *HLA-*341 *A*02:01* protein and initiating an immune response, we hypothesize that *HLA-*342 *A*02:01-KRAS*^{G12V} individuals might have an enhanced immune response 343 characterized by increased infiltration of anti-tumor immune cells, particularly $CDS⁺$ ³⁴⁴T cells, compared to those with the allele and another *KRAS* mutation. Conversely, 345 patients with *KRAS*^{G12D} mutated tumors might either produce less immunogenic 346 neoantigens or exhibit a higher infiltration of cells able to promote tumor tolerance. ³⁴⁷This results in a reduced ability of cytotoxic T cells to recognize and target the tumor 348 cells. Interestingly, we discovered that *KRAS*^{G12D} PDAC tumors exhibited higher ³⁴⁹expression levels of IFN-γ in comparison to other *KRAS* mutated tumors. The

350 differences in survival that we found in *KRAS*^{G12D} PDAC tumors might be due to 351 elevated IFN-γ levels upregulate PD-L1 expression, which binds to PD-1 receptors on ³⁵²T cells, inhibiting their activity and the recruitment of regulatory T cells (Tregs) and ³⁵³myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment (37). In 354 addition, high IFN PDAC tumors have been associated with worse overall survival, ³⁵⁵due to a higher activation of stroma contributing to tumor growth (38). Altogether 356 might explain the differences in survival that we found in $KRAS^{G12D}$ PDAC tumors. ³⁵⁷Consistently, a recent study published by Till et al., 2024, demonstrated that the 358 clearance of ct*KRAS*^{G12D} is associated with improved overall outcomes in metastatic 359 PDAC. This might be due to the immune system no longer recognizing the G12D 360 neoantigen, leading to reduced IFN- γ levels (39).

 361 Beyond $A*02:01$, we identified three additional alleles associated with PDAC 362 risk in our meta-analysis. Among them, *HLA-DPB1*04* was associated with an 363 increased risk of PDAC, with haplotypes containing this allele also showing an 364 increased risk. Limited information is available on the role of this allele in cancer (40). 365 Previous studies have shown that the risk allele *HLA-B*39* is associated with Grave's 366 disease (41) while the protective allele *HLA-B*49* has been inversely associated with ³⁶⁷COVID-19 (42). Nevertheless, our study is the first to report an association between 368 these alleles and cancer risk. Finally, *HLA-A*26:01* was associated with an increased 369 risk of PDAC and inversely associated with nasal allergies and asthma in the 370 PanGenEU population. These results point to a possible explanation of previous 371 findings showing an inverse association between atopic comorbidities and PDAC risk ³⁷²(10). While the meta-analysis combining PanGenEU and UKB data threw a risk 373 estimate (OR=1.07), it lacked statistical significance. This could be accounted for by 374 the low AF of $HLA-A*26:01$ in UKB population (0.02) vs the AF in PanGenEU

³⁷⁵(0.06), the latter AF being similar in most European countries with UK differing in the ³⁷⁶AF by >50%. *HLA-A*26:01* has been reported to be associated with an increased risk 377 of non-Hodgkin lymphoma (OR=8.5, p-value=2.6x10⁻²) (43). Importantly, including 378 these alleles in a non-genetic-based cumulative risk score significantly altered the risk 379 of developing PDAC, either increasing or decreasing it substantially.

380 Our study has some limitations. First, the analyses employed self-reported 381 epidemiological information from subjects included in the studies that could lead to ³⁸²misclassification of the risk factors and comorbidities, such as asthma and rhinitis. ³⁸³However, our meta-analysis using the estimates of both PanGenEU and UKB 384 populations allowed us to minimize this potential bias. In addition, we restricted the 385 analyses to the Caucasian population; therefore, the impact of *HLA* alleles on PDAC 386 risk and prognosis in other ethnic groups should be further assessed. Additionally, the ³⁸⁷*MHC* region is one of the most polymorphic areas of the human genome, making it 388 challenging for association analyses to detect rare alleles that may play a crucial role 389 in PDAC risk.

390 Despite the above-mentioned limitations, our work has several strengths. We 391 performed an in-depth analysis of the relationship between the *HLA* region and PDAC 392 risk by employing state-of-the-art methodology using important resources from two ³⁹³large and independent study populations with complementary designs: case-control ³⁹⁴and cohort. We corrected for population stratification by adjusting for the PCAs. ³⁹⁵Additionally, the association with PDAC prognosis was first conducted with 396 PanGenEU study and further validated with data from three additional independent 397 datasets: UKB, TCGA, PAN-NGS, and Caris.

398 Our findings provide a strong basis for $HLA-A*02:01$, a single biomarker to be ³⁹⁹considered in improving PDAC prevention and risk stratification, allowing for

⁴¹⁰**MATERIAL AND METHODS**

⁴¹¹*Ethics Statement*

412 IRB ethical approval and written informed consent were obtained by all participating 413 centers contributing to PanGenEU, and study participants, respectively. The study was 414 conducted in accordance with the Helsinki Declaration.

415

⁴¹⁶*Study populations*

⁴¹⁷In this study, we employed the resources of the PanGenEU case-control study, the ⁴¹⁸UKB cohort, and datasets from The Cancer Genome Atlas (TCGA), PAN-NGS trial 419 from Erasmus Medical Center (EMC), Rotterdam, and Caris trial from Vall d'Hebron 420 University Hospital (VHIO), Barcelona.

⁴²¹*PanGenEU study* details have been reported elsewhere (9–11,44). It is a 422 multicentric case-control study on PDAC conducted in 28 centers across Spain, Italy, 423 Sweden, Germany, the UK, and Ireland from 2009-2014 and 2016-2018. Newly 424 diagnosed PDAC patients over 18 years of age were recruited. Eligible controls were ⁴²⁵hospital inpatients with primary diagnoses not associated with any of the well-known ⁴²⁶PDAC risk factors. Controls for Ireland and Sweden were population-based. ⁴²⁷Epidemiological information was collected through direct in-person interviews by 428 trained health monitors using structured questionnaires, including information about 429 lifestyle, environmental exposures, and medical history (9). The individuals were 430 genotyped with the Infinium OncoArray-500K (45) and missing genotypes were 431 imputed using IMPUTE2 v2 (46) and 1000Genomes (Phase 3, v1) as reference (47). ⁴³²Quality control filters included the missing call rate, unexpected heterozygosity, ⁴³³discordance between reported and genotyped gender, unexpected relatedness, and 434 estimated European ancestry < 80%. Once those samples were filtered out, genotyped 435 data from 1,317 cases and 700 controls were employed for *HLA* allele imputation and 436 association analyses.

⁴³⁷*UKB* is a prospective cohort study of approximately 500,000 individuals from 438 the United Kingdom (48). The UKB Axiom array was used for genotyping 450,000 439 subjects, and the remaining 50,000 individuals were genotyped with the UK BiLEVE 440 Axiom array. Based on their primary International Classification of Diseases (ICD9 ⁴⁴¹and ICD10) codes, we selected 935 PDAC patients (**Supplementary Table S8**). We 442 discarded the self-reported cases $(N=45)$ to ensure PDAC diagnosis reliability and 443 those individuals with no Caucasian genetic ethnicity ($N=129$), resulting in a final set 444 of 761 PDAC cases. After selecting Caucasian individuals without a history of cancer ⁴⁴⁵and with the same ICD9 and ICD10 codes as PanGenEU controls (10), the final 446 dataset of controls included 95,050 subjects.

⁴⁴⁷*TCGA*, established in 2006 by the National Cancer Institute and the National ⁴⁴⁸Human Genome Research Institute, is one of the largest databases of cancer genomics 449 data (49). TCGA has genetic information for 33 cancer types, genotyped with the ⁴⁵⁰Affymetrix 6.0 SNP array. We collected information on outcome, *HLA* alleles typed 451 with the Optitype tool (50), and *KRAS* mutations from PDAC, colorectal, stomach ⁴⁵²adenocarcinoma, and Non-Small Cell Lung Cancer (NSCLC) patients. We kept for the ⁴⁵³analysis Caucasian individuals and those patients with complete data, 101 PDAC, 185 454 colorectal, 196 stomach adenocarcinoma, and 620 NSCLC. Additionally, we ⁴⁵⁵employed data from Thorsson et al, 2018 to assess the immune landscape of the 101 456 TCGA PDAC tumors.

457 The PAN-NGS trial (CCMO ID NL75415.078.20) includes PDAC patients 458 from twelve centers throughout the Netherlands who were prospectively recruited 459 from April 2021 to June 2023. Local review committees approved the trial. Eligible

460 patients had cytologically or histologically confirmed PDAC, were aged 18-60 years ⁴⁶¹at diagnosis, had an Eastern Cooperative Oncology Group performance score of 0-2, 462 and had an estimated life expectancy of at least twelve weeks. Patients were excluded ⁴⁶³when they did not want to know if alterations might be associated with genetic ⁴⁶⁴predisposition of cancer or in case of locally advanced or local recurrence of PDAC 465 without histological tissue readily available. Clinical data were collected at 466 participating centers and supplemented as needed. Clinical information was obtained 467 at the site of the participating centers, and missing information was requested if were 468 also treated in other hospitals. A final dataset of 108 PDAC patients was employed for 469 the subsequent analysis.

⁴⁷⁰*Caris clinical trial* is a retrospective single-center dataset involving patients 471 with PDAC treated at Vall d'Hebron University Hospital between 2021 and 2023. ⁴⁷²Eligible participants were over 18 years old, had histologically confirmed PDAC, and 473 underwent molecular analysis with the Caris Life Sciences sequencing panel. ⁴⁷⁴Exclusion criteria were non-adenocarcinoma pancreatic tumors, poor-quality samples 475 unsuitable for sequencing, inadequate follow-up, or lack of written informed consent. 476 Clinical data were collected at diagnosis, and a multidisciplinary team assessed the ⁴⁷⁷clinical stage. The Ethics Committee of the Vall d'Hebron University Hospital ⁴⁷⁸(PR(AG)651/2023) approved the study. Complete data was obtained for 145 PDAC 479 patients and included in the analysis.

⁴⁸¹*HLA (or MHC) alleles assessment*

⁴⁸²*HLA* class I and II alleles were first imputed using genotyped data from the ⁴⁸³PanGenEU study. We took advantage of the imputed *HLA* alleles from UKB, TCGA, 484 Erasmus MC, and Caris subjects.

UKB information on 362 *HLA* alleles across eleven loci (*HLA-A*, -*B*, -*C*, - *DPB1*, -*DPA1*, -*DQB1*, -*DQA1*, -*DRB1*, -*DRB2*, -*DRB3*, -*DRB4*, and -*DRB5*) was 501 available and obtained through the HLA*IMP:02 program (54).

TCGA: *HLA* class I alleles from the colorectal, stomach, and NSCLC tumors 503 were inferred from normal WES using polysolver (55). Then, xHLA (56) was employed to infer the *HLA* I and *HLA* II alleles (*HLA-A*, -*B*, -*C*, -*DPB1*, -*DQB1*, and - *DRB1*) from normal WES of the PDAC patients.

Erasmus MC: *HLA* genotype results were determined based on information 507 from mRNA isolated from a formalin-fixed paraffin-embedded tumor sample using 508 the Agilent SureSelectXT Low Input Library prep chemistry, optimized for FFPE

509 tissue, in conjunction with the SureSelect Human All Exon V7 bait panel (48.2 Mb)

510 and the Illumina NovaSeq.

Caris clinical trial: HLA genotypes were obtained from Caris Life Sciences reports for all patients. Genomic DNA was isolated from microdissected, formalin-513 fixed paraffin-embedded tumor samples and analyzed using the Illumina NovaSeq 6000 sequencers. A hybrid pull-down panel of baits designed to enrich for more than 700 clinically relevant genes at high coverage and high read-depth was used, along 516 with another panel designed to enrich for additional $>20,000$ genes at a lower depth. 517 To assist with gene amplification/deletion measurements and other analyses, a 500Mb SNP backbone panel (Agilent Technologies) was included. Analytical validation for *HLA* genotyping showed >99% concordance with a validated comparator method.

⁵²¹*HLA haplotype assessment*

⁵²²We inferred the haplotypes independently in each population using the *haplo.stats*^R 523 package (57) after phasing with BEAGLE (58) and considering the *HLA* gene 524 combinations prevalent in the Net Allele Database (28). A final set of 3,129 525 haplotypes were inferred in the PanGenEU individuals using 262 1-field *HLA* alleles 526 across all eight loci with an info parameter reflecting imputation quality >0.3 . In the ⁵²⁷UKB study, a final set of 148 and 57 1-field *HLA* class I and *HLA* class II haplotypes, 528 respectively, were identified using 141 1-field *HLA* alleles. No *HLA* haplotype 529 assessment was done for the TCGA population.

⁵³¹*Statistical analyses*

532 We assessed the association between the *HLA* region and PDAC risk for the individual ⁵³³*HLA* alleles and haplotypes within each study population. Subsequently, we combined

534 the summary statistics using a meta-analysis approach. Then, we studied the 535 association of the *HLA* alleles with well-established PDAC risk factors. Additionally, 536 we investigated the heritability explained by *HLA* class I and class II alleles (**Fig. 1**). ⁵³⁷We did not consider further the analysis at the amino-acid level because significant 538 results at the individual level were not found (**Supplementary Table S9**). Finally, 539 prognostic analyses integrated *HLA* alleles and *KRAS* mutational profiles.

⁵⁴¹*HLA allele-based association analysis with PDAC risk.* Association analyses were 542 done using the *PLINK* V1.9 software (59). In the PanGenEU setting, we tested the 543 association between the *HLA* alleles and PDAC risk at the individual level by 544 estimating the Odds Ratios (OR) and 95% Confidence Intervals (CI) through logistic 545 regression models including age, gender, the European region, and the first five 546 principal components (PCAs) to correct for population stratification. We considered 547 the three Modes of Inheritance (MoI) for 424 PanGenEU *HLA* class I and II alleles ⁵⁴⁸with AF >0.05. In UKB, we included the I- and II-fields *HLA* alleles with an AF 549 $>0.1\%$ (60,61). We performed logistic regression models adjusting for the same 550 covariates as in the PanGenEU models, plus the type of genotyping array and center of 551 inclusion.

552 A posterior meta-analysis using a random-effects model was performed with 553 the *rma.uni* function of the *metafor* R package (62), combining the risk estimates of 554 *HLA* alleles for PDAC with a nominal p-value < 0.1 from the association analysis in 555 PanGenEU and UKB studies, followed by multiple testing correction.

556

⁵⁵⁷*HLA allele-based association analysis with established PDAC risk factors.* We used 558 logistic regression models to assess the association between *HLA* alleles significantly

559 associated with PDAC risk in the previous meta-analyses with established PDAC risk 560 factors such as Family History of Pancreatic Cancer (FHPC), T2DM, obesity, and 561 tobacco and alcohol consumption, as well as with PDAC protective factors (asthma 562 and nasal allergies). We restricted these analyses to the controls from each study. ⁵⁶³Then, we performed a meta-analysis by applying a random-effects model. A 564 cumulative PDAC risk score for the most promising alleles was computed by using 565 the estimates obtained in the meta-analysis including PanGenEU and UKB.

566

⁵⁶⁷*Haplotype association analysis.* We used the *haplo.stats* R package (version 1.7.9) to ⁵⁶⁸perform the statistical association analysis of the PanGenEU and UKB *HLA* 569 haplotypes with PDAC risk. We employed a logistic regression model adjusted for the 570 same covariates as in the previous analyses. We considered the three MoIs in each 571 study population. Multiple testing correction was applied for each gene combination 572 separately after discarding the low prevalence *HLA* haplotypes (i.e., frequencies either 573 $\leq 5\%$ or $\leq 0.1\%$ in PanGenEU and UKB, respectively).

⁵⁷⁵*Estimation of the heritability explained by HLA class I and class II alleles*

⁵⁷⁶We applied a Bayesian multi-kernel-based regression (63) to estimate the genetic 577 variance explained by *HLA* class I and *HLA* class II alleles using the resources of the 578 PanGenEU study:

$$
y = X\beta + Zh_I + Zh_II + \varepsilon
$$

579 where the response variable y is a vector of case/control outcomes, \boldsymbol{X} is an incidence 580 or design matrix relating the adjusting covariates to each individual, β is the 581 corresponding regression coefficient, \boldsymbol{z} is a design matrix allocating records ((y) to the vector of *HLA* class I/II associated risk scores (h_l and h_{l_l}), and **ε** is a vector of random

583 normal deviates with null mean and variance σ_{ε}^2 that includes model misspecification 584 and environmental effects not considered in this model. The two genetic and residual 585 variances were assumed to follow the distributions $h_l \sim N(0, H I \sigma_{HLA-I}^2)$, 586 $N(0, H_{II} \sigma_{HLA-II}^2)$ and $\varepsilon \sim N(0, I \sigma_{\varepsilon}^2)$, where H_I and H_{II} correspond to the *HLA* class I and 587 *HLA* class II alleles-derived relationship matrices between individuals, σ_{HLA-I}^2 and 588 σ_{HLA-II}^2 are the genetic variances explained by *HLA* class I and II alleles, **I** is an 589 identity matrix, and σ_{ε}^2 corresponds to the residual variance. The prior distribution for 590 the genetic and residual variances were inverted chi-square distributions.

591 H_I and H_{II} similarity matrices were constructed using a Gaussian kernel with 592 the *G.matrix* function of *snpReady* R package (64). Estimates of the unknown 593 parameters were obtained from their posterior distributions using a Gibbs sampling 594 implemented in the *BGLR* R package. We ran a McMC chain of 500,000 iterations, 595 and the first 100,000 were discarded as burn-in.

596

HLA allele-based survival analysis with PDAC risk. We assessed patient survival based on the presence or absence of the *HLA* alleles, with a strong prior on *HLA-A*02:01*. To this end, we used the survival data of 425 PDAC cases from PanGenEU, 506 from UKB, 101 from TCGA (98 when we account for the stage of the tumor), and 145 from the Caris clinical trial. First, we assessed the overlap of the *HLA* class I and II alleles between the three study populations. We computed Hazard Ratios (HR) and 95%CI using Cox proportional-hazards regression models for each population 604 separately under (co-)dominance MoIs. Adjustment covariates in PanGenEU models were sex, age at diagnosis, center, tumor stage, and the first PCAs; for UK Biobank, we included sex, age at diagnosis, genotyping array type, recruitment center and the 607 first five PCAs; for the TCGA and Caris models, we considered sex, age at diagnosis,

⁶⁰⁸and tumor stage. Finally, we meta-analyzed the results from the four populations using

- 609 the function *rma.uni* from the *metafor* R package.
- 610

⁶¹¹*Association analysis between HLA-A*02:01 and KRAS common mutations.* Based on 612 previous reports pointing to a joint effect of $HLA-A*02:01$ and *KRAS* mutations ⁶¹³(31,36), we further explored the interaction between these biomarkers using TCGA 614 data. We first assessed the association between *HLA-A*02:01* and well-established ⁶¹⁵*KRAS* missense mutations at codons 12 (G12A, G12C, G12D, G12F, G12R, G12S, ⁶¹⁶G12V), 13 (G13C, G13D), and 61 (Q61H, Q61K, Q61L, Q61R) using logistic 617 regression models in tumors with high proportion of *KRAS* mutations (PDAC, ⁶¹⁸colorectal, stomach, and NSCLC) (**Supplementary Table S10**). As the reference 619 category, we used the non-G12V mutations for PDAC and colorectal cancer and the 620 non-G12C for NSCLC. We initially assessed the association within each specific 621 cancer type individually. Subsequently, we pooled the data from all cancer types into a 622 single model, adjusting for cancer type. Finally, we used a Cox proportional-hazards 623 regression model to evaluate whether the interaction between $HLA-A*02:01$ and the 624 specific *KRAS*^{G12V} and *KRAS*^{G12D} mutations was associated with overall survival in ⁶²⁵PDAC. The same covariates mentioned in the previous paragraph and the Moffit 626 subtype of the tumor were employed to adjust these models. We used a Wilcoxon test 627 to evaluate whether the associations found in overall survival could be explained by 628 infiltrated immune components. Differences were considered significant at p-629 value<0.05.

⁶³⁰To validate the interaction between the HLA-A*02:01 and the *KRAS* 631 mutations, we used data from two independent populations, the Erasmus MC study 632 and the Caris clinical trial. We analyzed the interaction between the *HLA-A*02:01*

⁶⁴⁰**DECLARATIONS**

⁶⁴¹**Availability of data and materials:** The datasets generated and/or analyzed during 642 the current study are not publicly available due to the sensitive nature of genetic data 643 but are available from the corresponding author upon reasonable request.

⁶⁴⁴**Competing interests:** The authors declare that they have no competing interests.

Funding: The work was partially supported by Pancreatic Cancer Collective (PCC): 646 Lustgarten Foundation $&$ Stand-Up to Cancer (SU2C #6179); Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI061614, #PI11/01542, #PI0902102, #PI12/01635, #PI12/00815, #PI15/01573, #PI18/01347, #PI21/00495); Red Temática de Investigación Cooperativa en Cáncer, Spain (#RD12/0036/0034, #RD12/0036/0050, #RD12/0036/0073); EU-6FP Integrated 651 Project (#018771-MOLDIAG-PACA), EU-FP7-HEALTH (#259737-CANCERALIA, #256974-EPC-TM-Net); Associazione Italiana Ricerca sul Cancro (IG 26343); 653 Fondazione Cariverona: Oncology Biobank Project "Antonio Schiavi" (prot. 203885/2017); Italian Ministry of Health through Fondazione Italiana Malattie Pancreas (FIMP_CUP J37G22000230001); Cancer Focus Northern Ireland and Department for Employment and Learning; and ALF (#SLL20130022), Sweden, 657 Cancer Research UK (C7690/A26881) and Pancreatic Cancer UK.

Authors' contributions: Study conception: NM, ELM. Design of the work: AL, RR, ELM, NM. Data acquisition: RTL, AC, CvE, TM, MH, MI, XM, JML, CM, JP, MO, VMB, AT, AF, LMB, TCJ, EFM, TG, WG, LS, IF, GS, LLC, JB, EC, LI, JK, BK, 661 JM, DO, AS, WY, JY, FXR, NM, and rest of the PanGenEU Investigators. Data 662 analysis: AL, LA, SS, ELM. Interpretation of data: AL, RR, FXR, ELM, NM. Creation of new software used in the work: No one. Drafting the work or substantively

664 revising it: AL, RR, FXR, ELM, NM. Approval of the submitted version (and any 665 substantially modified version that involves the author's contribution to the study): ⁶⁶⁶ALL AUTHORS. Agreement on both to be personally accountable for the author's 667 own contributions and to ensure that questions related to the accuracy or integrity of 668 any part of the work, even ones in which the author was not personally involved, are ⁶⁶⁹appropriately investigated, resolved and the resolution documented in the literature:

670 ALL AUTHORS.

⁶⁷¹**Acknowledgements** The authors thank the patients, coordinators, field and 672 administrative workers, and technicians of the European Study into Digestive Illnesses 673 and Genetics (PanGenEU) and TCGA studies. This research has been conducted using 674 the UK Biobank Resource under Application Number 47884. This research was 675 performed using resources generated by Type 1 Diabetes Genetics Consortium, a 676 collaborative clinical study sponsored by the National Institute of Diabetes and 677 Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious 678 Diseases (NIAID), National Human Genome Research Institute (NHGRI), National 679 Institute of Child Health and Human Development (NICHD), and Juvenile Diabetes ⁶⁸⁰Research Foundation International (JDRF) and supplied by NIDDK Central 681 Repository (NIDDK-CR). This manuscript was not prepared under the auspices of the ⁶⁸²T1DGC study and does not necessarily reflect the opinions or views of the T1DGC 683 study, study sponsors, NIDDK-CR, or NIH. The results here are in part based upon 684 data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

⁶⁸⁶**REFERENCES**

- 687 1. Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating
688 omics and clinical data. Nat Rev Cancer. Nature Publishing Group; 2022;22:131–42 68866 omics and clinical data. Nat Rev Cancer. Nature Publishing Group; 2022;22:131–42.
- 689 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for
690 Clinicians. 2020:70:7–30. Clinicians. 2020;70:7–30.
- 691 3. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an
692 overview. Nat Rev Gastroenterol Hepatol. Nature Publishing Group: 2009:6:699–708 ⁶⁹²overview. Nat Rev Gastroenterol Hepatol. Nature Publishing Group; 2009;6:699–708.
- 693 4. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England 694 cancers combined and survival adjusted for age and sex for each cancer in England and
695 Wales, 1971-2011: a population-based study. Lancet. 2015;385:1206–18. ⁶⁹⁵Wales, 1971-2011: a population-based study. Lancet. 2015;385:1206–18.
- 696 5. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of Cancer
697 Incidence in the United States: Burdens Upon an Aging. Changing Nation. JCO. V 697 Incidence in the United States: Burdens Upon an Aging, Changing Nation. JCO. Wolters
698 Kluwer: 2009:27:2758–65 Kluwer; 2009;27:2758-65.
- ⁶⁹⁹6. Singhi AD, Koay EJ, Chari ST, Maitra A. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology. 2019;156:2024-40.
- 701 7. Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer —
702 clinical challenges and opportunities. Nat Rev Clin Oncol. Nature Publishing Group: 702 clinical challenges and opportunities. Nat Rev Clin Oncol. Nature Publishing Group;
703 2020:17:527–40. 2020;17:527-40.
- 704 8. Gobbi PG, Bergonzi M, Comelli M, Villano L, Pozzoli D, Vanoli A, et al. The prognostic role of time to diagnosis and presenting symptoms in patients with p 705 prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. Cancer Epidemiology. 2013:37:186–90. cancer. Cancer Epidemiology. 2013;37:186–90.
- 707 9. Gomez-Rubio P, Zock J-P, Rava M, Marquez M, Sharp L, Hidalgo M, et al. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut. BMJ 708 risk of pancreatic cancer associated with asthma and nasal allergies. Gut. BMJ
709 Publishing Group: 2017:66:314–22. Publishing Group; 2017;66:314–22.
- 710 10. Gomez-Rubio P, Piñero J, Molina-Montes E, Gutiérrez-Sacristán A, Marquez M, Rava
711 M. et al. Pancreatic cancer and autoimmune diseases: An association sustained by 711 M, et al. Pancreatic cancer and autoimmune diseases: An association sustained by
712 computational and epidemiological case–control approaches. International Journal 712 computational and epidemiological case–control approaches. International Journal of 713 Cancer. 2019:144:1540–9. Cancer. 2019;144:1540-9.
- 714 11. López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-715 Antoniano IA, et al. A multilayered post-GWAS assessment on genetic susceptibility to
716 mancreatic cancer. Genome Med. 2021:13:15. pancreatic cancer. Genome Med. 2021;13:15.
- 717 12. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, et al. Association
718 analysis identifies 65 new breast cancer risk loci. Nature. Nature Publishing Grour 718 analysis identifies 65 new breast cancer risk loci. Nature. Nature Publishing Group;
719 2017:551:92–4. ⁷¹⁹2017;551:92–4.
- 720 13. Lan Q, Hsiung CA, Matsuo K, Hong Y-C, Seow A, Wang Z, et al. Genome-wide
721 secondarion analysis identifies new lung cancer susceptibility loci in never-smokin 721 association analysis identifies new lung cancer susceptibility loci in never-smoking
722 women in Asia. Nat Genet. Nature Publishing Group: 2012:44:1330–5. women in Asia. Nat Genet. Nature Publishing Group; 2012;44:1330-5.
- 723 14. Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, et al.
724 Sasociation of variations in HLA class II and other loci with susceptibility to EGFR-724 Association of variations in HLA class II and other loci with susceptibility to EGFR-
725 mutated lung adenocarcinoma. Nat Commun. Nature Publishing Group: 2016:7:1245 mutated lung adenocarcinoma. Nat Commun. Nature Publishing Group; 2016;7:12451.

888 Table 1. Cumulative PDAC risk estimates (OR: odds ratio and CI: confidence interval) in the extreme scenarios according to the presence/absence of known risk

889 interval) in the extreme scenarios according to the presence/absence of known risk
890 factors (Type II diabetes, smoking, and family history of pancreatic cancer, FHPC) or

890 factors (Type II diabetes, smoking, and family history of pancreatic cancer, FHPC) or protective factors (asthma and nasal allergies) in addition to the significant HLA

891 protective factors (asthma and nasal allergies) in addition to the significant *HLA*
892 alleles identified in the meta-analysis.

alleles identified in the meta-analysis.

Scenario a: smokers, diabetics or individuals with family history of cancer who did not have asthma nor allergies in the meta-
894 scenario b: asthmatic or allergic individuals who did not smoke, did not have diabetes, nor

894 analysis of the PangenEU and UK Biobank population.
895 Scenario b: asthmatic or allergic individuals who did no 895 Scenario b: asthmatic or allergic individuals who did not smoke, did not have diabetes, nor family history of cancer.
896

896
897

⁸⁹⁸**MAIN FIGURE LEGENDS**

- ⁸⁹⁹**Figure 1**. Study Flowchart: Overview of the complementary approaches adopted in 900 this study to explore the role of *MHC* region in the PDAC susceptibility and 901 prognosis.
- ⁹⁰²**Figure 2**. Odds ratio (OR) and 95% confidence interval (CI) of the association 903 analyses between PDAC susceptibility alleles, as well as the allele frequency (AF): 904 *HLA-A*02:01* (Figure 2A), *HLA-B*49* (Figure 2B), *HLA-B*39* (Figure 2C), and *HLA-*⁹⁰⁵*DPB1*04* (Figure 2D) obtained in the meta-analysis and known risk/protective factors
- 906 for PDAC.

⁹⁰⁷**Figure 3.** Hazard ratio (HR) and 95% confidence interval (CI) of the Cox 908 proportional-hazards regression models under a dominance MoI obtained in the meta-909 analysis for the allele *HLA-A*02:01* when considering PanGenEU, UK Biobank, and 910 TCGA (Figure 3A), and when including data from the Caris clinical trial in the meta-911 analysis (Figure 3B).

⁹¹²**Figure 4.** Kaplan-Meier curves of patients according to their KRAS mutational status 913 in *HLA-A*02:01* carriers with PDAC tumors harboring *KRAS*^{G12V} patients whose 914 tumors have other KRAS mutations who are carriers of *HLA-A*02:01* (Figures 4A 915 and Figure 4C) and non-carriers of that allele (Figures 4B and Figure 4D).

⁹¹⁶**Figure 5.** Kaplan-Meier curves of patients according to the presence or absence of the 917 *HLA-A*02:01* allele in *KRAS*^{G12V} (Figures 5A) and *KRAS*^{G12V} (Figures 5B) mutated 918 tumors.

⁹¹⁹**Figure 6.** Hazard ratio (HR) and 95% confidence interval (CI) of the Cox 920 proportional-hazards regression models under a dominance MoI obtained in the meta-

- 921 analysis for the allele *HLA-A*02:01* for (A) stages I&II PDAC tumors from Erasmus
- 922 and TCGA study populations and (B) stages III&IV tumors from Erasmus MC and
- 923 Caris study populations.

924

⁹²⁵**Additional Files**

- **Annex 1.** PanGenEU Investigators.
- Table S1. Baseline characteristics of the study populations.
- **Table S2**. Number of alleles of *HLA* Class I and Class II genes considered in the association analysis in each study population after filtering out the alleles with poor imputation quality.
- **Table S3**. *HLA* allele, 95% confidence intervals bounds (ci.lb and ci.ub), odds ratios (OR), p-value, and adjusted p-value and of the association metaanalysis between the *HLA* alleles and pancreatic ductal adenocarcinoma (PDAC) risk including the PanGenEU and UK Biobank study populations.
- **Table S4.** *HLA* allele, frequency (Freq), Imputation quality (INFO), odds ratios (OR), p-value, and adjusted p-value and of the association between the *HLA* alleles and pancreatic ductal adenocarcinoma (PDAC) risk in the PanGenEU study population.
- **Table S5.** *HLA* allele, frequency (Freq), odds ratios (OR), p-value, and adjusted pvalue and of the association meta-analysis between the *HLA* alleles and pancreatic ductal adenocarcinoma (PDAC) risk in the UK Biobank study population.
- **Table S6.** Frequency in both populations (freq), Odd ratio (OR), confidence interval (CI), and p-value (p) of the inferred haplotypes from *MHC* I and II *HLA* genes significantly associated with PDAC risk by genome-wide association studies considering an additive mode of inheritance.
- **Table S7.** Odd ratio (OR) and p-value (p) of the association between *HLA-A**02:01 and *KRAS* mutations across three different tumor types from TCGA data: PDAC, colorectal, and NSCLC (we excluded stomach because there was only one individual with G12V mutations).
- **Table S8.** ICD9 and ICD10 codes for PDAC in UK Biobank
- **Table S9.** Amino acid (AA), base pair (BP), Frequency (Freq), odds ratios (OR), p-value, and adjusted p-value and of the association between the HLA amino acids and pancreatic ductal adenocarcinoma (PDAC) risk in the PanGenEU study populations.
- **Table S10.** *KRAS* mutational status of PDAC, colorectal, stomach, and NSCLC cancer types from the TGCA study.
- **Figure S1.** Whole landscape of the alleles of *HLA* class I and II genes at two-fields in PanGenEU (Figure S1A) and in UKBiobank (Figure S1B) study populations. The x-axis shows each of the imputed *HLA* alleles across the 8 studied loci. The y-axis, represents the frequency in the PanGenEU

and UK Biobank populations for each *HLA* allele.

- **Figure S2.** Scatter plots of the HLA allele frequencies in PanGenEU study population versus in T1DGC, which was used as a reference panel to impute the 1-field (Figure S2A) and 2- fields (Figure S2B) *HLA* alleles in PanGenEU.
- **Figure S3.** Scatter Plot of the allele frequencies in PanGenEU and UK Biobank populations, showing a moderate agreement.
- **Figure S4.** Odds ratio (OR) and 95% confidence interval (CI) of the association analyses between *HLA-A*26:01* and PDAC risk and PDAC risk/protective factors in PanGenEU population. FHPC: Family history of PC; BMI: body mass index.
- **Figure S5.** Venn diagram illustrating the overlap of *HLA* Class I and II gene alleles at two fields in the PanGenEU, UKBiobank, and TCGA study populations.
- **Figure S6.** Hazard ratio (HR) and 95% confidence interval (CI) of the Cox proportional-hazards regression models under a codominance MoI obtained in the meta-analysis for the allele *HLA-DPB1*04* when considering PanGenEU, UK Biobank, and TCGA.
- **Figure S7.** Hazard ratio (HR) and 95% confidence interval (CI) of the Cox proportional-hazards regression models obtained under the additive MoI in the meta-analysis of three populations for the 2-field alleles *HLA-A*30:01* and *HLA-DPB1*09:01*.
- **Figure S8.** Boxplot showing the significant differences in IFN-γ levels between PDAC tumors with *KRAS*^{G12D} mutations vs any of the other KRAS mutated tumors obtained through the Wilcoxon test.
- **Figure S9.** Hazard ratio (HR) and 95% confidence interval (CI) of the Cox proportional-hazards regression models obtained under the additive MoI in the meta-analysis of three populations for the interaction between the *HLA-A*02:01* allele with $KRAS^{G12V}$ mutations.

926

*Cases/controls

Figure 5

 $+$ Non-A*02:01 + A*02:01 $G12V$

 $Non-G12V$ $+$ Non-A*02:01 + A*02:01 **Figure 6**

